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Abstract
Background: Outbreaks of Hendra (HeV) and Nipah (NiV) viruses have been reported starting in 1994 and 1998, 
respectively. Both viruses are capable of causing fatal disease in humans and effecting great economical loss in the 
livestock industry.
Results: Through screening of hybridomas derived from mice immunized with γ-irradiated Nipah virus, we identified 
two secreted antibodies; one reactive with the nucleocapsid (N) protein and the other, the phosphoprotein (P) of 
henipaviruses. Epitope mapping and protein sequence alignments between NiV and HeV suggest the last 14 amino 
acids of the carboxyl terminus of the N protein is the target of the anti-N antibody. The anti-P antibody recognizes an 
epitope in the amino-terminal half of P protein. These monoclonal antibodies were used to develop two antigen 
capture ELISAs, one for virus detection and the other for differentiation between NiV and HeV. The lower limit of 
detection of the capture assay with both monoclonal antibodies was 400 pfu. The anti-N antibody was used to 
successfully detect NiV in a lung tissue suspension from an infected pig.
Conclusion: The antigen capture ELISA developed is potentially affordable tool to provide rapid detection and 
differentiation between the henipaviruses.
Background
Since their first occurrences in 1994 and 1998 respec-
tively, the Hendra (HeV) and Nipah (NiV) viruses have
caused recurrent outbreaks throughout northeastern
Australia and southern Asia [1-5]. Fruit bats of the genus
Pteropus have been identified as the primary reservoirs of
these viruses [6-9]. Thoroughbred horses and farmed
pigs, respectively, were the intermediate hosts between
the bat reservoir and humans in the initial outbreaks
[10,11]. Since then, several HeV infections had only
occurred in horses and no intermediate host was identi-
fied in the subsequent NiV outbreaks in India and Ban-
gladesh [5,12-14].
Four fatalities have been reported in 7 cases of human
HeV infections [15]. Human case fatalities in NiV out-
breaks varied from 38% in Malaysia up to 92% in Bangla-
desh [2,10,12,13]. The higher case fatalities in the
Bangladesh outbreaks could be attributable to bias in
selection of admissible patients and lack of adequate
healthcare system [2]. Both HeV and NiV are categorized
as Biosafety Level 4 (BSL4) Select Agents by the US
National Select Agent Program [16,17].
Because HeV and NiV share unique genetic and anti-
genic features, a distinct genus Henipavirus, was created
within the family Paramyxoviridae [18-20]. Alignments
of NiV and HeV amino acid sequences demonstrate simi-
larities ranging from 92.1% for the nucleocapsid (N) pro-
tein to 67.6% for the phosphoprotein (P) [19,21]. The
divergence in amino acid sequences between NiV and
HeV P proteins suggests that it is a potential candidate
antigen for differential detection of NiV and HeV.
Infections by NiV or HeV in humans and animals can
be confirmed by serologic tests as well as by detection of
viral proteins, viral RNA or by virus isolation [16]. The
most commonly used serologic assays are ELISAs using
infected cell lysate antigens and the specificity of these
IgG and IgM ELISA systems for detecting infection with
henipaviruses approaches 95% [16]. Recombinant N pro-
tein has been used as an alternative antigen for serologi-
cal detections of henipaviruses in the absence of a BSL4
facility required to generate NiV or HeV infected cell
lysate [16,22-25]. Results from ELISA assays can be con-
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firmed by other serologic tests including plaque reduc-
tion neutralization [26,27]. A number of sensitive RT-
PCR assays have been described for detection of viral
RNA [28,29] and these have been used to support out-
break investigations and research. Viral antigen capture
ELISA would also provide a high throughput format at
relatively low cost. Such assays could be adapted into
bedside or pen-side tests to perform rapid detection of
henipaviruses in field or clinical settings [30,31].
In this report, we have taken the first steps to develop
antigen capture tests for HeV and NiV by characterizing
two monoclonal antibodies against the Henipavirus P and
N proteins. The 2B10 p4 antibody specifically binds and
captures HeV P/V/W proteins. The anti-N antibody 1A11
C1 captures proteins from HeV and both NiV Malaysia
and Bangladesh strains with high sensitivities, and was
able to detect NiV antigen from a pig lung specimen fro-
zen since the Malaysian NiV outbreak. The advantage of
this cost-effective assay is that it enables rapid processing
of large numbers of specimens, and it can complement
the current diagnostic tools for henipaviruses used both
in the field and the laboratory.
Results
Specificities of monoclonal antibodies to henipaviruses
During the initial rounds of cloning and screening of the
hybridomas, two hybridomas (1A11 and 2B10) were
selected for their ability to recognize major proteins from
HeV and NiV infected Vero cell lysates (Figure 1A). The
1A11 antibody recognized a protein similar in size to the
N  p r o t e i n  ( ~ 5 8  k D a )  f r o m  H e V  a s  w e l l  a s  f r o m  b o t h
strains of NiV (Malaysia and Bangladesh). The 2B10 anti-
body detected a protein of slightly less than 100 kDa from
2 NiV strains and HeV. It also weakly reacted with a pro-
tein similar in size to the N protein in all infected lysates
(Figure 1A). These two hybridomas were subjected to
further cloning and screening against cell lysates contain-
ing individual NiV Malaysia protein P, V, W, C or N, that
were expressed from plasmid DNA. The resulting anti-
body from 1A11 C1 was specific for the N protein (Figure
1B). Antibody from 2B10 p4 strongly recognized the P
protein (migrated with apparent molecular weights
between 80 and 98 kDa) and a more weakly product of
approximately ~40 kDa, which likely represents a degra-
dation or premature termination product. In addition,
2B10 p4 could also weakly detect the V and W proteins
(55 kDa, Figure 1B). The C protein which is translated
from an alternative reading frame on the P gene was not
recognized by either antibody (Figure 1B). Antibody iso-
types of 1A11 C1 and 2B10 p4 were determined as IgG2a
and IgG1, respectively.
Epitope mapping of 1A11 C1 and 2B10 p4
To determine the linear epitope of monoclonal antibody
1A11 C1, 24 or 25-mers of non-overlapping peptides
spanning over the entire N protein sequence of NiV were
screened by direct ELISA. Only a C-terminal peptide (a.a.
509-532) yielded specific signals above the 10 ng/ml con-
centration of plate-coated peptide (Figure 2). The epitope
in this C-terminal region was not only detected by NiV
hyperimmune mouse ascites fluid (HMAF) but also by
HeV HMAF, rabbit anti-HeV serum and a pool of NiV
sero-positive swine sera from the 1999 Malaysia outbreak
(Figure 3). The overall pattern of shared epitopes among
polyclonal antibodies could be observed regardless of the
source of immunogen (NiV or HeV) or the mammals
from which the antibodies were generated (Figure 3).
Figure 1 Characterizations of antibodies produced by hybrido-
mas. (A) The 4-12% gradient gels were loaded with cell lysate equiva-
lent to 2 μg of protein in each lane as follows, lane 1 and 2 (also lane 6 
and 7) represent 2 preparations of NiV Malaysia infected Vero cell 
lysates; lane 3 and 8, NiV Bangladesh infected Vero cell lysate; lane 4 
and 9, HeV infected Vero cell lysate; lane 5 and 10, control Vero cell 
lysate. After gel separation and transferring, membranes were probed 
with culture supernatant from 1A11 and 2B10. (B) 293T cells were 
transfected with NiV Malaysia P, V, W, C or N proteins expressed from 
plasmids. Ten μL of each cell lysate was separated by SDS-PAGE. Mono-
clonal antibodies purified from cloned hybridomas were diluted 1 to 
2000 and incubated with transferred membranes. Lane M, ladder of 
MagicMark™ XP Western Protein Standard from Invitrogen.
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Interestingly, the rabbit anti-HeV serum bound to a dis-
tinct epitope (a.a.101-124) which was not recognized by
antibodies generated from other animal species (Figure
3). Several human convalescent sera from the 1999 out-
break did not react to the C terminal peptide of the N
protein (Figure 3).
The V and W proteins of henipaviruses are transcribed
from the same reading frame as the P protein until reach-
ing the internal mRNA editing site in the P gene [32-34].
We have shown that 2B10 p4 recognized protein prod-
ucts generated from P gene transcripts (NiV P, V, and W
proteins) by Western blot (Figure 1B). This suggests that
the epitope of 2B10 p4 is located within the common N-
terminal sequence (a.a. 1-407) of these proteins. How-
ever, linear epitope mapping over this region did not
result in any peptide binding even with the inclusion of
reported single phosphorylated site at Ser-240 [21] (Data
not shown).
Antigen capture from infected Vero cell lysates
Monoclonal antibodies 1A11 C1 and 2B10 p4 were fur-
ther analyzed to test their abilities to capture native viral
proteins on ELISA plates. Antibody 1A11 C1 was able to
detect NiV Malaysia, NiV Bangladesh and HeV from
infected Vero cell lysates (Figure 4A, B and 4C). Success-
ful detection of N proteins was achieved at dilutions
ranging 1:1 to 1:7290, with the cutoff value derived from
3 times the standard deviation of the average OD of the
uninfected cell lysate controls being 0.2-0.3. The P/V/W
specific antibody 2B10 p4 could only detect NiV proteins
at very low dilutions (1:1 to 1:270, Figure 4A and 4B);
however, applying infected cell lysate at a dilution less
than 1:270 resulted in increased non-specific signals (e.g.
Marburg hemorrhage fever (MHF) virus HMAF coated
controls in Figure 4A, B and 4C). The 2B10 p4 captured
HeV P/V/W protein at cell lysate dilutions of 1:1 to
1:2340 (Figure 4C).
Sensitivity of antigen capture ELISA
Serial dilutions of titrated virus stocks (NiV Malaysia pro-
totype and HeV) were prepared in buffer containing non-
ionic detergent and tested on antigen capture ELISA
coated with 1A11 C1 or 2B10 p4 (Figure 5A and 5B).
Antibody 1A11 C1 was capable of capturing NiV or HeV
at virus titer of log 3.6 pfu/mL (400 pfu per well). The
anti-P 2B10 p4 antibody detects HeV at a comparable
sensitivity as 1A11 C1 (Figure 5B), but had poor ability to
bind NiV (Figure 5A) similar to results obtained with the
infected Vero cell lysate (Figure 4A). Dilutions of Lassa
virus were included as the background control to calcu-
late the cutoff value of the assay (0.21, Figure 5A and 5B).
Detection of NiV in pig tissue by antigen capture ELISA
In order to evaluate antigen capture ELISA, cell suspen-
sions from γ-irradiated pig tissue specimens from the
Malaysian outbreak in 1999 were prepared as target anti-
gens on plates coated with monoclonal antibody 1A11
C1. The results of the antigen capture assay are shown
alongside data from RT-PCR, virus isolation, immunohis-
tochemistry (IHC), and antibody detections [10] in Table
1. A low titer of NiV N antigens was detected in the lung
of pig 55 using the antigen capture assay (Table 1). Posi-
tive RT-PCR, virus isolation and IHC results also con-
firmed the existence of NiV in the lung of this pig (Table
Figure 2 Epitope mapping of mAb 1A11 C1 using direct ELISA. 
Synthetic peptides corresponding to the complete NiV N protein se-
quence (a.a. 1-532) were serial diluted and coated at concentration 
from 1 μg to 0.1 ng per well (100 μL in volume). A peptide from Alkhur-
ma virus E protein (Alk E, a.a. 143-168) was included as negative control 
and signal cutoff value (0.17) was calculated based on readings from 
this peptide. NiV infected Vero lysate diluted 10 fold to 105 fold were 
served as positive control.
Figure 3 Diagram of antibody epitopes on NiV N protein se-
quence. In addition to the epitope of mAb 1A11 C1, linear epitope 
mappings were performed with a panel of polyclonal antibodies on 
NiV N peptides: NiV and HeV hyperimmune mouse ascites fluid 
(HMAF), Rabbit anti-HeV serum, NiV infected human convalescent se-
rum and a pool of NiV seropositive swine sera. The boxes with illustrat-
ed patterns represent the degree of interaction on direct ELISA, and 
their a.a. positions in N protein sequence were also indicated above.Chiang et al. Virology Journal 2010, 7:115
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1). However, the antigen capture assay did not detect viral
antigen in the lung and brain of Pig 5, although RT-PCR
and virus isolation performed at the time of the outbreak
confirmed NiV infections in the lung of Pig 5 (Table 1).
No virus was detected in the brain, lung, or kidney of Pig
4 and 59 by capture ELISA, RT-PCR, virus isolation, or
IHC (Table 1). No IgM or IgG response was detected dur-
ing the time of outbreak in the serum of these pigs (Table
1). Due to the shortage of outbreak specimens, we were
unable to determine the sensitivity and specificity of anti-
gen capture ELISA on tissue samples.
Discussion
Up until the present, all the reported cases or outbreaks
of infection with henipaviruses were within the geo-
graphical distribution of Pteropus spp. [6,8,9]. These bats
appear to settle into subpopulations with limited interac-
tions among colonies [1]. NiV and HeV apparently
remain separate within their hosts and respective regions
with little overlap [1]. On the other hand, other families
of bats were often found coexisting in the same colony
with Pteropus. Antibodies reactive with Nipah virus were
found in Eidolon dupreanum in Madagascar [35]. Fur-
thermore, other novel henipavirus-like sequences and
cross-reacting antibodies have recently been identified in
Eidolon helvum from Ghana, West Africa [36,37], which
potentially implicates much wider endemic regions of
henipaviruses than previously known.
Here we report two monoclonal antibodies that recog-
nized native conformations of N and P/V/W proteins of
henipaviruses. In previous studies, monoclonal antibod-
Figure 4 Antigen capture ELISAs for the detection of NiV or HeV 
from infected cell lysate. Serial dilutions of (A) NiV Malaysia proto-
type, (B) NiV Bangladesh or (C) HeV infected Vero cell lysate was tested 
with mAbs 1A11 C1 and 2B10 p4 on antigen capture ELISA. Marburg 
virus (MHF) HMAF was included as negative antibody control. Data 
points represent the means ± standard deviations from 5 replicates. 
Signal cutoff values were calculated based on uninfected Vero cell 
lysate controls.
Figure 5 Sensitivities of antigen capture ELISAs for titrated NiV 
and HeV stocks. (A) NiV Malaysia prototype stock (4.1 × 106 pfu/mL) 
and (B) HeV stock (1.9 × 106 pfu/mL) were serial diluted onto wells coat-
ed with 1A11 C1 and 2B10 p4. Marburg virus (MHF) HMAF was includ-
ed as negative antibody control and signals above this antibody 
control were shown (Adjusted OD). Lassa virus stock (1 × 108 pfu/mL) 
was used as negative virus control and signal cutoff value was calculat-
ed based on its OD readings.
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ies were produced either through phage display library
screening, or using chemically inactivated virus/recombi-
nant viral protein immunizations [22-26,38-40]. The
hybridomas in our study originated from mice immu-
nized with γ-irradiated virus, and the secreted antibodies
recognized native viral proteins. Linear epitope mapping
on NiV N sequence indicates the epitope of 1A11 C1 is
located within the last C-terminal 23 amino acids (a. a.)
of the N protein (509-532). Alignment data of the C ter-
minal area of N protein between NiV and HeV further
indicated that the last 14 a.a. (520-532) were identical
between the two viruses [41], and would likely represent
the actual epitope. Interestingly, this epitope is located
right after the N-P interaction site (a.a. 468-496) on the N
protein [41]. Epitope mapping of other monoclonal anti-
bodies to recombinant N protein or phage library screen-
ing of infected swine sera did not identify the C terminus
of N protein as a site of antibody recognition [40,42]. In
addition, linear epitope mappings against the NiV N pro-
tein sequence using ascites fluids, sera from immunized
animals or infected humans/pigs were performed and
compared. The C terminal peptide of N protein was
found to be a strong epitope recognized by all of poly-
clonal antibodies tested except for NiV infected human
convalescent sera.
Our antigen capture ELISA, using plates coated with
anti-N 1A11 C1 antibodies was capable of detecting HeV
and NiV at a lower limit of detection of 4000 pfu/mL
which is comparable to detection sensitivities reported in
other antigen detection ELISAs [43,44]. The 1A11 C1 or
2B10 p4 antigen detection assay also demonstrated its
specificity by low background signal cutoff values for
uninfected Vero cell lysate and Lassa virus. In addition,
when using high dilutions of NiV/HeV infected Vero cell
lysates (≥ 1: 300), non-specific signals were kept below
background levels when polyclonal antibodies against
MHF or Crimean-Congo hemorrhagic fever (CCHF)
virus (data not shown) were coated on the plate.
Monoclonal antibody 1A11 C1 was also shown to cap-
ture NiV from one frozen pig lung specimen from the ini-
tial Malaysian NiV outbreak. However, corresponding
RT-PCR and virus isolation results obtained at the time of
the outbreak suggest the assay failed to identify another
infected pig. A previous study had shown virus titers of 5
× 107, 2.5 × 103, and 6.3 × 105 pfu/g of swine CSF, lung,
and spleen tissues, respectively [45]. In our antigen detec-
tion assay, 10% tissue suspension (wt/vol) was used as the
origin of serial dilutions. Virus loads in some tissue may
be too low to be detected at this dilution range. Further-
more, viral degradation resulting from long term storage
may further compromise the results of antigen capture
E L I S A.  U n f o r t u n a t e l y ,  w e  w e r e  u n a b l e  t o  c o n f i r m  t h i s
possibility by repeating RT-PCR and virus isolation since
tissue samples were irradiated.
A previous study has described using monoclonal anti-
bodies against N and M proteins to differentiate NiV
from HeV by Western blot [38]. In our study, 2B10 p4
antibody specifically captured native HeV P/V/W pro-
teins and could only detect NiV proteins at high virus
concentration or by Western blot. These results suggest
that the binding affinity of 2B10 p4 could be influenced
by how its epitope was presented by the P proteins of NiV
and HeV. In fact, we were unable to identify linear epitope
of 2B10 p4 from the NiV Malaysia P sequence despite
knowing it should be located within the shared N-termi-
nal sequence of P/V/W protein (a.a. 1-407). In contrast,
polyclonal HMAF raised against NiV was able to recog-
nize 6 individual plate-coated peptides in this region by
direct ELISA (data not shown).
NiV and HeV soluble recombinant G proteins coated
on beads had previously been developed and utilized in a
Bio-Plex protein array to differentiate between infections
with these viruses [37,46]. As the G proteins of these
viruses share 83.3% homology [19] and the assay would
be assessing polyclonal antibodies present in clinical
specimens, it is unclear to what extent the ability to dif-
ferentiate between the viruses would be maintained on
analysis of diverse specimens from humans, bats or pigs.
One of the advantages of the antigen capture assay
Table 1: Diagnostic result of NiV infections in pigsa.
Pig no Capture ELISAb RT-PCRc Virus isolation IHCc Abd
4- - - - -
5- + + N D -
55 + (lung, 4) + + + -
59 - - - - -
a+ or -, samples positive or negative on capture ELISA, RT-PCR, virus isolation, IHC and antibody detection.
bPositive identified tissue and the reciprocal titer of 10% tissue suspension in parentheses.
cLung tissue samples were used in RT-PCR and IHC. Primer sequences and procedures were described in [10]. ND, not done.
dBoth serum IgM and IgG detection assays were performed.Chiang et al. Virology Journal 2010, 7:115
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described here is that it is based on the P protein of NiV
and HeV which is highly diverse and share only 67.6%
homology [19], which may facilitate the ability to robustly
differentiate among infections with henipaviruses.
Real time RT-PCR has been shown to detect Nipah
virus with high sensitivity and specificity [28,29]. How-
ever, nested RT-PCR using broad-range primers and
sequencing may be required to identify newly emerging
henipaviruses [36,47]. Although further validation for our
antigen capture assay will be needed once HeV and NiV
infected tissue specimens are available, this relatively
inexpensive and robust diagnostic tool could be useful in
broad spectrum surveys for detection of henipaviruses.
Conclusions
Two monoclonal antibodies were selected to set up anti-
gen capture ELISAs for Henipavirus. Mab 1A11 C1 rec-
ognized C terminus of N protein of both NiV and HeV
with high sensitivity. 2B10 p4 was found to bind Hendra
P/V/W with good specificity. While the applications of
NiV/HeV infection by our antigen capture ELISAs
remain to be fully evaluated, we believe these assays could
offer economical and rapid sample processing for any
future outbreaks of henipaviruses.
Methods
Virus stocks, cell lysates, and pig tissue suspensions
Hendra virus strain 9409-30-1800 Australia was origi-
nated from a horse lung sample from Brisbane, Australia
in 1994. Both Nipah virus strain SPB199901924 Malaysia
prototype and strain SPB200401617 Bangladesh were iso-
lated from CSF of patients in the 1999 and 2004 out-
breaks, respectively. Lassa virus Josiah strain isolated
from human in Sierra Leone was used as the control virus
stock. Viruses were inoculated in Vero-E6 cell and propa-
gated until CPE reached 3-4+ before harvest. Viruses
w e r e  t i t r a t e d  b y  p l a q u e  a s s a y s  o n  V e r o - E 6  c e l l s  a s
described [48]. The attached cells were scraped and cen-
trifuged, washed before lysed in borate saline containing
1% Triton X-100, pH 9. The sample was frozen at -70°C
and gamma irradiated at 5 × 106 Rad. The resulting mate-
rial was sonicated and centrifuged to obtain cell lysate.
Control Vero cell lysate was made the same way except no
virus infection was performed.
For pig tissue samples from 1999 Malaysia outbreak
[10], 10% (wt/vol) suspensions of thawed frozen tissue
sections (~250 mg) were homogenized on ice in Hank's
balance salt solution (HBSS)/5% fetal calf serum with a
plastic pestle and 250 mg of alundum (Fischer Scientific,
Pittsburgh, PA) in 15 mL conical tubes. The tissue sus-
pensions were clarified by low speed centrifugation
before using in antigen capture ELISA as follows.
Nipah hybridomas and monoclonal antibodies
Twenty five μL of Nipah virus Malaysian prototype stock
was i.c. injected into suckling mice in BSL4 laboratory.
The brain of the sick suckling mouse was taken out by day
3, γ-irradiated and used for following immunizations.
Four weeks old BALB/C mice (Charles River Laborato-
ries, Wilmington, MA) were immunized i.p.  with 10%
suckling mouse brain, HBSS and 0.05 M Tris buffer, pH 9
emulsified with Ribi adjuvant (Ribi ImmunoChem
Research Inc., Hamilton, MT) in 200 μL. Two booster
injections of 100 μL were given on days 21 and 35. Mice
serum antibody titers were monitored by ELISA and IFA
in between boosters. One hundred μL of brain homoge-
nate without adjuvant was injected at day 56 and 4 days
later, the splenocytes of the immunized mice were iso-
lated and fused with NS-1 (TIB-18) myeloma cells.
Hybridomas were screened for secretion for desired anti-
bodies by ELISA and IFA. Western blot was used for con-
firmations of monoclonality and specificity of the
antibody. Protein G 8 mL or Protein A 36 mL column
connected to an ÄKTAprime™ plus system (GE Health-
care, Piscataway, NJ) was used for purification of mono-
clonal antibody from supernatants from hybridoma
cultures. Antibodies were concentrated in Amicon 50 mL
Stirred Ultrafiltration Cells (Millipore, Billerica, MA).
The isotype of purified monoclonal antibody was deter-
mined by IsoStrip Mouse Monoclonal Antibody Isotyp-
ing Kit (Roche Diagnostics, Indianapolis, IN).
Western blot
HEK 293T cells were transfected with expression plas-
mids containing P, V, W, C, or N as previously described
[34]. Cells were lysed in RIPA buffer (150 mM NaCl, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris
Buffer , pH 8). T en μL of cell lysate was separated on a
NuPAGE™ 4-12% Bis-Tris gel (Invitrogen, Carlsbad, CA),
then transferred onto a PVDF membrane by iBlot™ Gel
Transfer System (Invitrogen). After Blocking with PBS
containing 0.05% Tween-20 and 5% skim milk, the mem-
brane was incubated with hybridoma cell supernatant
overnight at 4°C. PBS containing 0.05% Tween-20 was
used for thorough washing before HRP- conjugated anti-
body was added to incubation. Signals were developed by
using SuperSignal™ West Dura Extended Duration Sub-
strate (Thermo Scientific, Waltham, MA).
Epitope mapping
Non-overlapped 24, 25 or 26-mer peptides spanning N-
terminal half (a.a. 1-407) sequence of Nipah P protein
(NCBI Reference Sequence, Accession no: NP_112022)
and the entire sequence (a.a. 1-532) of Nipah N protein
(NCBI Reference Sequence, Accession no: NP_112021)
were synthesized and RP-HPLC purified by the Biotech-
nology Core Facility in CDC. Peptides were dissolved inChiang et al. Virology Journal 2010, 7:115
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water before transferring to microtiter plates, and dried
at 37°C overnight as described [49]. The wells were
blocked with 100 μL of PBS containing 0.1% Tween-20
and 5% skim milk for 1 hour then washed with PBS con-
taining 0.1% Tween-20. The monoclonal antibody (2B10
p4 or 1A11 C1) or polyclonal antibody (NiV HMAF, HeV
HMAF, rabbit anti-HeV serum, NiV infected human con-
valescent or a pool of NiV seropositive swine sera) was
diluted into 1 μg/mL (monoclonal) or 1 to 1000 (poly-
clonal) with blocking buffer. The antibody was added and
incubated for 1 hour at 37°C. The secondary HRP-conju-
gated goat anti-mouse IgG (Thermo Fisher Scientific,
Rockford, IL), goat anti-rabbit IgG (Bio-Rad, Hercules,
CA), mouse anti-human IgG Fc (Accurate, Westbury,
NY), or goat anti-swine IgG (KPL, Gaithersburg, MD) in
1:8000 was added after washing. After one hour of incu-
bation, color development was measured as described in
the following ELISA protocol.
Antigen capture ELISA
The design and setup of antigen capture ELISA for heni-
pavirus were based on the assay developed for Ebola virus
as described previously [43,50]. Five μg/mL of monoclo-
nal antibody (1A11 C1 or 2B10 p4) in 100 μL/well were
coated onto each well of microtiter plates (BD Falcon, San
Jose, CA) overnight at 4°C. Wells were blocked for an
hour at 37°C with PBS containing 0.1% Tween-20 and 5%
skim milk then washed with PBS containing 0.1% Tween-
20, which also included in subsequent steps. Henipavirus
stocks, infected Vero-E6 cell lysate or euthanized pig tis-
sue suspension were serial-diluted with PBS containing
0.1% Tween-20 and 5% skim milk in 100 μL on plate then
incubated for one hour at 37°C. Rabbit anti-HeV poly-
clonal antibody diluted 2000 fold was added and incu-
bated for an hour at 37°C. The wells were incubated with
goat anti-rabbit HRP conjugate (Bio-Rad) at a dilution of
1:8000 for 1 hour at 37°C. The peroxidase reaction was
developed with ABTS (2, 2'-azino-bis (3-ethylbenzthiazo-
line-6-sulphonic acid)) substrate system (KPL) for 30 min
and optical density (OD) was read at 410 nm (Dynatech
MR5000). The OD value subtracted by the background
value of control uninfected Vero cell lysate or tissue sus-
pension incubated with coated Marburg virus HMAF
(1:1000) was indicated as "Adjusted OD". Test samples
were considered positive if their mean OD were greater
than the mean OD of uninfected Vero cell lysate or tissue
suspension incubated with coated monoclonal antibodies
plus 3 times of their standard deviation (indicated as the
signal cutoff value).
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
CFC performed much of the Nipah and Hendra virus Western blots, ELISAs, and
drafted the manuscripts, MKL prepared transfected 293T cell lysates containing
NiV proteins and contributed to manuscript preparation, PAR and CFS pro-
vided valuable opinions to the results and also contributed to manuscript
preparation, PER oversaw the overall assay designs, coordinated study support,
and assisted manuscript preparation and submission. All authors have read
and approved the final version of this manuscript.
Acknowledgements
Hybridoma subcloning, monoclonal antibody purification and peptide synthe-
sis were performed by Suyu Ruo, members in Biologics Branch and Biotechnol-
ogy Core Facility of CDC. We would like to acknowledge Zachary Reed, David 
Miller, Shelley Campbell, Aridth Gibbons, Gregory Kocher, and Deborah Can-
non for their assistance in reagent preparation and data collection. Michael Lo 
was supported by an American Society for Microbiology postdoctoral fellow-
ship. The authors also thank to Drs. Brian Harcourt and Wun-Ju Shieh for pro-
viding RT-PCR and immunohistochemistry data of 1999 Malaysia outbreak, and 
Dr. Stuart Nichol for his support in this study.
Author Details
1Special Pathogens Branch, Division of Viral and Rickettsial Diseases, Centers for 
Disease Control and Prevention, Atlanta, Georgia, USA and 2Measles, Mumps, 
Rubella and Herpes Viruses Laboratory Branch, Division of Viral Diseases, 
Centers for Disease Control and Prevention, Atlanta, Georgia, USA
References
1. Wild TF: Henipaviruses: a new family of emerging Paramyxoviruses.  
Pathol Biol 2009, 57:188-196.
2. Lo MK, Rota PA: The emergence of Nipah virus, a highly pathogenic 
paramyxovirus.  J Clin Virol 2008, 43:396-400.
3. Guillaume V, Wong KT, Looi RY, Georges-Courbot MC, Barrot L, Buckland 
R, Wild TF, Horvat B: Acute Hendra virus infection: Analysis of the 
pathogenesis and passive antibody protection in the hamster model.  
Virology 2009, 387:459-465.
4. Hsu VP, Hossain MJ, Parashar UD, Ali MM, Ksiazek TG, Kuzmin I, Niezgoda 
M, Rupprecht C, Bresee J, Breiman RF: Nipah virus encephalitis 
reemergence, Bangladesh.  Emerg Infect Dis 2004, 10:2082-2087.
5. Playford EG, McCall B, Smith G, Slinko V, Allen G, Smith I, Moore F, Taylor C, 
Kung YH, Field H: Human Hendra virus encephalitis associated with 
equine outbreak, Australia, 2008.  Emerg Infect Dis 2010, 16:219-223.
6. Wacharapluesadee S, Boongird K, Wanghongsa S, Ratanasetyuth N, 
Supavonwong P, Saengsen D, Gongal GN, Hemachudha T: A longitudinal 
study of the prevalence of Nipah virus in Pteropus lylei bats in Thailand: 
Evidence for seasonal preference in disease transmission.  Vector Borne 
Zoonotic Dis 2010, 10:183-190.
7. Yob JM, Field H, Rashdi AM, Morrissy C, van der Heide B, Rota P, bin Adzhar 
A, White J, Daniels P, Jamaluddin A, Ksiazek T: Nipah virus infection in 
bats (order Chiroptera) in peninsular Malaysia.  Emerg Infect Dis 2001, 
7:439-441.
8. Field H, Young P, Yob JM, Mills J, Hall L, Mackenzie J: The natural history of 
Hendra and Nipah viruses.  Microbes Infect 2001, 3:307-314.
9. Eaton BT, Broder CC, Middleton D, Wang LF: Hendra and Nipah viruses: 
different and dangerous.  Nat Rev Microbiol 2006, 4:23-35.
10. Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, Ksiazek TG, 
Rollin PE, Zaki SR, Shieh W, et al.: Nipah virus: a recently emergent deadly 
paramyxovirus.  Science 2000, 288:1432-1435.
11. Murray K, Selleck P, Hooper P, Hyatt A, Gould A, Gleeson L, Westbury H, 
Hiley L, Selvey L, Rodwell B: A morbillivirus that caused fatal disease in 
horses and humans.  Science 1995, 268:94-97.
12. Harcourt BH, Lowe L, Tamin A, Liu X, Bankamp B, Bowden N, Rollin PE, 
Comer JA, Ksiazek TG, Hossain MJ, et al.: Genetic characterization of 
Nipah virus, Bangladesh, 2004.  Emerg Infect Dis 2005, 11:1594-1597.
13. Hossain MJ, Gurley ES, Montgomery JM, Bell M, Carroll DS, Hsu VP, 
Formenty P, Croisier A, Bertherat E, Faiz MA, et al.: Clinical presentation of 
Nipah virus infection in Bangladesh.  Clin Infect Dis 2008, 46:977-984.
14. Chadha MS, Comer JA, Lowe L, Rota PA, Rollin PE, Bellini WJ, Ksiazek TG, 
Mishra A: Nipah virus-associated encephalitis outbreak, Siliguri, India.  
Emerg Infect Dis 2006, 12:235-240.
15. Voelker R: Promising antibody fights lethal viruses.  JAMA 2009, 
302:2643.
Received: 5 May 2010 Accepted: 3 June 2010 
Published: 3 June 2010
This article is available from: http://www.virologyj.com/content/7/1/115 © 2010 Chiang et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Virology Journal 2010, 7:115Chiang et al. Virology Journal 2010, 7:115
http://www.virologyj.com/content/7/1/115
Page 8 of 8
16. Daniels P, Ksiazek T, Eaton BT: Laboratory diagnosis of Nipah and Hendra 
virus infections.  Microbes Infect 2001, 3:289-295.
17. Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, 
McEachern JA, Green D, Hancock TJ, Chan YP, et al.: A neutralizing human 
monoclonal antibody protects against lethal disease in a new ferret 
model of acute Nipah virus infection.  PLoS Pathog 2009, 5:e1000642.
18. Harcourt BH, Tamin A, Ksiazek TG, Rollin PE, Anderson LJ, Bellini WJ, Rota 
PA: Molecular characterization of Nipah virus, a newly emergent 
paramyxovirus.  Virology 2000, 271:334-349.
19. Wang L, Harcourt BH, Yu M, Tamin A, Rota PA, Bellini WJ, Eaton BT: 
Molecular biology of Hendra and Nipah viruses.  Microbes Infect 2001, 
3:279-287.
20. Mayo MA: Names of viruses and virus species - an editorial note.  Arch 
Virol 2002, 147:1463-1464.
21. Shiell BJ, Gardner DR, Crameri G, Eaton BT, Michalski WP: Sites of 
phosphorylation of P and V proteins from Hendra and Nipah viruses: 
newly emerged members of Paramyxoviridae.  Virus Res 2003, 92:55-65.
22. Chen JM, Yu M, Morrissy C, Zhao YG, Meehan G, Sun YX, Wang QH, Zhang 
W, Wang LF, Wang ZL: A comparative indirect ELISA for the detection of 
henipavirus antibodies based on a recombinant nucleocapsid protein 
expressed in Escherichia coli.  J Virol Methods 2006, 136:273-276.
23. Eshaghi M, Tan WS, Ong ST, Yusoff K: Purification and characterization of 
Nipah virus nucleocapsid protein produced in insect cells.  J Clin 
Microbiol 2005, 43:3172-3177.
24. Juozapaitis M, Serva A, Zvirbliene A, Slibinskas R, Staniulis J, Sasnauskas K, 
Shiell BJ, Wang LF, Michalski WP: Generation of henipavirus 
nucleocapsid proteins in yeast Saccharomyces cerevisiae.  Virus Res 2007, 
124:95-102.
25. Yu F, Khairullah NS, Inoue S, Balasubramaniam V, Berendam SJ, Teh LK, 
Ibrahim NS, Abdul Rahman S, Hassan SS, Hasebe F, et al.: Serodiagnosis 
using recombinant Nipah virus nucleocapsid protein expressed in 
Escherichia coli.  J Clin Microbiol 2006, 44:3134-3138.
26. Crameri G, Wang LF, Morrissy C, White J, Eaton BT: A rapid immune 
plaque assay for the detection of Hendra and Nipah viruses and anti-
virus antibodies.  J Virol Methods 2002, 99:41-51.
27. Tamin A, Harcourt BH, Lo MK, Roth JA, Wolf MC, Lee B, Weingartl H, 
Audonnet JC, Bellini WJ, Rota PA: Development of a neutralization assay 
for Nipah virus using pseudotype particles.  J Virol Methods 2009, 
160:1-6.
28. Guillaume V, Lefeuvre A, Faure C, Marianneau P, Buckland R, Lam SK, Wild 
TF, Deubel V: Specific detection of Nipah virus using real-time RT-PCR 
(TaqMan).  J Virol Methods 2004, 120:229-237.
29. Gurley ES, Montgomery JM, Hossain MJ, Bell M, Azad AK, Islam MR, Molla 
MA, Carroll DS, Ksiazek TG, Rota PA, et al.: Person-to-person transmission 
of Nipah virus in a Bangladeshi community.  Emerg Infect Dis 2007, 
13:1031-1037.
30. Muller JD, McEachern JA, Bossart KN, Hansson E, Yu M, Clavijo A, 
Hammond JM, Wang LF: Serotype-independent detection of foot-and-
mouth disease virus.  J Virol Methods 2008, 151:146-153.
31. Ferris NP, Abrescia NG, Stuart DI, Jackson T, Burman A, King DP, Paton DJ: 
Utility of recombinant integrin alpha v beta6 as a capture reagent in 
immunoassays for the diagnosis of foot-and-mouth disease.  J Virol 
Methods 2005, 127:69-79.
32. Kulkarni S, Volchkova V, Basler CF, Palese P, Volchkov VE, Shaw ML: Nipah 
virus edits its P gene at high frequency to express the V and W 
proteins.  J Virol 2009, 83:3982-3987.
33. Sleeman K, Bankamp B, Hummel KB, Lo MK, Bellini WJ, Rota PA: The C, V 
and W proteins of Nipah virus inhibit minigenome replication.  J Gen 
Virol 2008, 89:1300-1308.
34. Lo MK, Harcourt BH, Mungall BA, Tamin A, Peeples ME, Bellini WJ, Rota PA: 
Determination of the henipavirus phosphoprotein gene mRNA editing 
frequencies and detection of the C, V and W proteins of Nipah virus in 
virus-infected cells.  J Gen Virol 2009, 90:398-404.
35. Iehle C, Razafitrimo G, Razainirina J, Andriaholinirina N, Goodman SM, 
Faure C, Georges-Courbot MC, Rousset D, Reynes JM: Henipavirus and 
Tioman virus antibodies in pteropodid bats, Madagascar.  Emerg Infect 
Dis 2007, 13:159-161.
36. Drexler JF, Corman VM, Gloza-Rausch F, Seebens A, Annan A, Ipsen A, 
Kruppa T, Muller MA, Kalko EK, Adu-Sarkodie Y, et al.: Henipavirus RNA in 
African bats.  PLoS One 2009, 4:e6367.
37. Hayman DT, Suu-Ire R, Breed AC, McEachern JA, Wang L, Wood JL, 
Cunningham AA: Evidence of henipavirus infection in West African fruit 
bats.  PLoS One 2008, 3:e2739.
38. Berhane Y, Berry JD, Ranadheera C, Marszal P, Nicolas B, Yuan X, Czub M, 
Weingartl H: Production and characterization of monoclonal antibodies 
against binary ethylenimine inactivated Nipah virus.  J Virol Methods 
2006, 132:59-68.
39. Zhu Z, Bossart KN, Bishop KA, Crameri G, Dimitrov AS, McEachern JA, Feng 
Y, Middleton D, Wang LF, Broder CC, Dimitrov DS: Exceptionally potent 
cross-reactive neutralization of Nipah and Hendra viruses by a human 
monoclonal antibody.  J Infect Dis 2008, 197:846-853.
40. Xiao C, Liu Y, Jiang Y, Magoffin DE, Guo H, Xuan H, Wang G, Wang LF, Tu C: 
Monoclonal antibodies against the nucleocapsid proteins of 
henipaviruses: production, epitope mapping and application in 
immunohistochemistry.  Arch Virol 2008, 153:273-281.
41. Chan YP, Koh CL, Lam SK, Wang LF: Mapping of domains responsible for 
nucleocapsid protein-phosphoprotein interaction of henipaviruses.  J 
Gen Virol 2004, 85:1675-1684.
42. Eshaghi M, Tan WS, Yusoff K: Identification of epitopes in the 
nucleocapsid protein of Nipah virus using a linear phage-displayed 
random peptide library.  J Med Virol 2005, 75:147-152.
43. Ksiazek TG, Rollin PE, Jahrling PB, Johnson E, Dalgard DW, Peters CJ: 
Enzyme immunosorbent assay for Ebola virus antigens in tissues of 
infected primates.  J Clin Microbiol 1992, 30:947-950.
44. Saijo M, Georges-Courbot MC, Fukushi S, Mizutani T, Philippe M, Georges 
AJ, Kurane I, Morikawa S: Marburgvirus nucleoprotein-capture enzyme-
linked immunosorbent assay using monoclonal antibodies to 
recombinant nucleoprotein: detection of authentic Marburgvirus.  Jpn 
J Infect Dis 2006, 59:323-325.
45. Maisner A, Neufeld J, Weingartl H: Organ- and endotheliotropism of 
Nipah virus infections in vivo and in vitro.  Thromb Haemost 2009, 
102:1014-1023.
46. Bossart KN, McEachern JA, Hickey AC, Choudhry V, Dimitrov DS, Eaton BT, 
Wang LF: Neutralization assays for differential henipavirus serology 
using Bio-Plex protein array systems.  J Virol Methods 2007, 142:29-40.
47. Tong S, Chern SW, Li Y, Pallansch MA, Anderson LJ: Sensitive and broadly 
reactive reverse transcription-PCR assays to detect novel 
paramyxoviruses.  J Clin Microbiol 2008, 46:2652-2658.
48. Gupta M, Mahanty S, Bray M, Ahmed R, Rollin PE: Passive transfer of 
antibodies protects immunocompetent and imunodeficient mice 
against lethal Ebola virus infection without complete inhibition of viral 
replication.  J Virol 2001, 75:4649-4654.
49. Porzig R, Singer D, Hoffmann R: Epitope mapping of mAbs AT8 and Tau5 
directed against hyperphosphorylated regions of the human tau 
protein.  Biochem Biophys Res Commun 2007, 358:644-649.
50. Ksiazek TG, Rollin PE, Williams AJ, Bressler DS, Martin ML, Swanepoel R, 
Burt FJ, Leman PA, Khan AS, Rowe AK, et al.: Clinical virology of Ebola 
hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM 
antibody findings among EHF patients in Kikwit, Democratic Republic 
of the Congo, 1995.  J Infect Dis 1999, 179(Suppl 1):S177-187.
doi: 10.1186/1743-422X-7-115
Cite this article as: Chiang et al., Use of monoclonal antibodies against Hen-
dra and Nipah viruses in an antigen capture ELISA Virology Journal 2010, 
7:115